The emerging role of AKT inhibitors in breast cancer

The Emerging Role of PI3K InhibitionПодробнее

AKT inhibitors in research and applicationПодробнее

AKT inhibitors: a new type of targeted cancer drugПодробнее

The emerging role of SERD's in HR+ breast cancerПодробнее

IMPAKT 2013: The future of PI3K/AKT/mTOR inhibitors in breast cancerПодробнее

Data + Perspectives: HR-Positive Breast Cancer (1 of 5)Подробнее

The emerging role of immunotherapy for the treatment of early and advanced breast cancerПодробнее

Role of PI3K Inhibitors in HR+ Metastatic Breast CancerПодробнее

Hot Topics in Advanced Breast Cancer: 2023 Best of Breast ConferenceПодробнее

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment StrategiesПодробнее

Spotlight Poster Discussion: "Combined inhibition of CDK4/6 and AKT (LAR subtype)"Подробнее

PI3K-AKT Pathway ExplainedПодробнее

The role of the checkpoint inhibitors in breast cancerПодробнее

Addressing the Mechanism of Action for the AKT Pathway in TNBCПодробнее

Deciphering the Role of PI3K Mutations in HER2+ Breast CancerПодробнее

PI3K Inhibitors: A New Frontier in Cancer TreatmentПодробнее

Targeting the PI3K pathway in Breast CancerПодробнее

The mTOR pathway in ER+ advanced breast cancerПодробнее

Dr. Chandarlapaty on Role of the PI3K Pathway in Breast CancerПодробнее